Dr Reddy's Laboratories stock hit a fresh 52-week high of ₹1,413.1 on Monday, gaining 4.6% during the session. According to latest market reports, the pharmaceutical company's shares experienced significant momentum, reaching new peak levels. The stock is now trading near its lifetime high of ₹1,413 registered in August 2024, with the stock showing a positive bias for the last six trading sessions and soaring over 11% during this period. At 9:46 AM, Dr Reddy's stock was up 4.1% at ₹1,405, demonstrating sustained investor interest in the pharmaceutical company's shares. This marks the sixth consecutive day of gains for the stock, with the company's shares gaining 8.5% so far in the month of June, which has turned out to be its best month since December 2024, during which it had gained 15%.
The stock's rally was supported by near 3X jump in trading volume, with the counter seeing trades of around 1.95 lakh shares on the BUSINESS STANDARD as against the two-week average volume of around 72,000 shares. This dramatic increase in trading activity indicates heightened investor participation and significant market interest in the pharmaceutical company's shares. The substantial volume surge suggests increased investor confidence and active participation in the stock's movement during the trading session.
Dr Reddy's received seven observations from the USFDA following a pre-license inspection (PLI) of its biologics manufacturing facility at Bachupally, Hyderabad. According to the company's exchange filing, the USFDA completed the inspection between June 16 and June 25, 2026, and issued a Form 483 with seven observations. This follows two prior inspections, one in October 2023, during which it had received nine observations, and the other being in September 2025, during which the regulator had issued five observations to the facility. The company stated it will address these observations within the stipulated timeline, noting this is in continuation of earlier inspections made on October 12, 2023, and September 13, 2025. The inspection results were disclosed in an exchange filing on Thursday after market hours.
Brokerage firm Nomura maintained its "buy" rating on the stock with a price target of ₹1,740, the price target implying an upside potential of 29% from current levels. According to CNBC TV18, the brokerage noted that most of the observations issued by the USFDA this time around relate to the new facility, and that the long-standing contamination concerns, with regards to an old block may have been addressed by the company. Dr Reddy's Bachupally unit has two blocks, one is an older block, from which the biosimilar Rituximab was filed, and the other one is for the biosimilar abatacept. While Rituximab is a blood cancer treatment monoclonal antibody, Abatacept is a biological medication used in the modulation of the immune system to reduce inflammation. The company has also expressed confidence in resolving the observations and remains optimistic of approvals and drug launches in the January-May stretch of 2028.
Dr Reddy's has declared a final dividend of ₹8 per share, which will be paid to eligible shareholders as per the set record date of July 10, 2026. According to the company's exchange filing, the Board of Directors meeting scheduled for July 22, 2026, will consider and approve the un-audited standalone and consolidated financial results for the quarter ending June 30, 2026. This timeline provides investors with clear expectations for both dividend payments and quarterly results announcements.
Earlier in June, Dr Reddy's announced the first-to-market launch of Bosutinib tablets 400 mg, a generic equivalent of Bosulif, in the United States. As reported by Business Standard, the company collaborated with MSN Laboratories Private Limited on this product, with Dr. Reddy's holding exclusive marketing rights for the United States. According to IQVIA National Sales Perspectives data, the Bosulif brand (400mg) had US sales of approximately $253.8 million for the latest 12-month period ended April 2026. The launch expands Dr Reddy's oncology portfolio and reinforces its commitment to improving patient access to affordable, high-quality medicines.
